Heart and Lung

Juxtapid (lomitapide) gains FDA approval

Prescription bottle - BSN

(Best Syndication News) - The U.S. Food and Drug Administration (FDA) approved Juxtapid (lomitapide) to treat a rare homozygous familial hypercholesterolemia (HoFH) disorder. Juxtapid should lower the low-density lipoprotein (LDL) cholesterol levels, the total cholesterol, apolipoprotein B, and non-high-density lipoprotein (non-HDL) cholesterol. The drug should be prescribed in conjunction with a low fat diet and other lipid reduction treatments.

In the United States, around one in one million people have HoFH. People with the rare condition do not effectively remove “bad” LDL cholesterol from their body. This puts HoFH individuals at an increased risk for heart attacks and death, often before the age of 30.

Women who Smoke were at a higher Risk of Sudden Cardiac Death

Stethoscope - BSN

(Best Syndication News) - Women who smoke moderately are at a significantly higher risk than non-smokers to succumb to sudden cardiac death, according to a new study. The researchers reported their findings in the American Heart Association Journal, Circulation: Arrhythmia & Electrophysiology.

The risk factor for sudden cardiac death may even be higher in women who have smoked for a long time. However, over time, the risk factor could be reduced or eliminated by quitting the habit.

The study’s lead author, Roopinder K. Sandhu, M.D., M.P.H., a cardiac electrophysiologist at the University of Alberta's Mazankowski Heart Institute in Edmonton, Alberta, Canada, said that previous research has identified the risk for sudden cardiac death. In this new research, they wanted to determine the risk factor based on the quantity and duration of smoking. Sandhu and colleagues wanted to compare the risk factor to healthy women.

Healthy Diet reduced risk for having second Heart Attack or Stroke

Credit: National Cancer Institute Renee Comet (Photographer)

(Best Syndication News) - Eating a heart-healthy diet after having a heart attack or stroke can help prevent future events, according to a new study published in the American Heart Association journal Circulation.

Study author, Mahshid Dehghan, Ph.D, a nutritionist at the Population Health Research Institute, McMaster University in Hamilton, Ontario, Canada, said that if patients rely on medicine to lower their blood pressure and cholesterol, they may not think eating a heart-healthy diet is very important. The study found that dietary changes offer additional benefits to patients taking aspirin, angiotensin modulators, cholesterol lower medications, and beta-blockers.

Scientist identify More Genetic causes of Coronary Artery Disease

Blood pressure check - BSN

(Best Syndication News) - A large group of international scientists, including scientists from Standford University School of Medicine, has identified 15 new genetic areas that are related to coronary artery disease. With these new findings, there are now 46 genetic links related to heart disease. The research findings will be published in the December 2 online edition of Nature Genetics.

Coronary atherosclerosis, another name for plaque build-up in the artery wall of the heart vessels, is a condition that can cause a person to suffer chest pain or a heart attack. According the U.S. Centers for Disease Control, heart disease ranks as the leading cause of death in the United States.

Ranbaxy recalls 41 Lots of Atorvastatin Calcium Medication

Prescription bottle - BSN

(Best Syndication News) - Ranbaxy Inc. announced a voluntary recall of 41 lots of Atorvastatin Calcium Tablets (generic version of Lipitor) because small glass particles may be included with the medication. The particles could be the size of a grain of sand or even smaller.

The dosages of Atorvastatin, a cholesterol lowering medication, involved in the recall are 10 mg, 20 mg, and 40 mg. The 80 mg dose of the medication is not involved in the recall. The recall was announced by the U.S. Food and Drug Administration as well as on the company’s website.

Out of extreme precaution, Ranbaxy Laboratories Limited (NSE:RANBAXY)is recalling the product. They said that the likelihood of having an adverse reaction is unlikely, but it cannot be ruled out entirely. So far, Ranbaxy has not received any reports of problems associated with the glass. Ranbaxy has contacted distributors and retailers (pharmacies) to stop delivery. Customers are being asked to return the pills to their pharmacy.

Syndicate content
Share/Save/Bookmark

      

Post to Facebook

Important: The material on Best Syndication is for informational purposes only and is not meant to be advice. Authors may have or will receive monetary compensation from the company's product/s mentioned. You should always seek professional advice before making any legal, financial or medical decisions and this website cannot substitute or replace any trained professional consultation.
Use of this site means that you agree to our TERMS OF SERVICE

Advertise On This Site
Copyright © 2006-2015 By Best Syndication All Rights Reserved